Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 246

1.

Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease.

Yu ASL, Shen C, Landsittel DP, Grantham JJ, Cook LT, Torres VE, Chapman AB, Bae KT, Mrug M, Harris PC, Rahbari-Oskoui FF, Shi T, Bennett WM; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Kidney Int. 2019 May;95(5):1253-1261. doi: 10.1016/j.kint.2018.12.023. Epub 2019 Mar 4.

PMID:
30922668
2.

Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD).

Wong ATY, Mannix C, Grantham JJ, Allman-Farinelli M, Badve SV, Boudville N, Byth K, Chan J, Coulshed S, Edwards ME, Erickson BJ, Fernando M, Foster S, Haloob I, Harris DCH, Hawley CM, Hill J, Howard K, Howell M, Jiang SH, Johnson DW, Kline TL, Kumar K, Lee VW, Lonergan M, Mai J, McCloud P, Peduto A, Rangan A, Roger SD, Sud K, Torres V, Vilayur E, Rangan GK.

BMJ Open. 2018 Jan 21;8(1):e018794. doi: 10.1136/bmjopen-2017-018794. Erratum in: BMJ Open. 2018 Aug 5;8(8):e018794corr1.

3.

Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.

Brosnahan GM, Abebe KZ, Moore CG, Rahbari-Oskoui FF, Bae KT, Grantham JJ, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Miskulin DC, Steinman TI, Torres VE; HALT-PKD Trial Investigators.

Am J Kidney Dis. 2018 May;71(5):666-676. doi: 10.1053/j.ajkd.2017.10.023. Epub 2018 Jan 3.

4.

Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.

Yu ASL, Shen C, Landsittel DP, Harris PC, Torres VE, Mrug M, Bae KT, Grantham JJ, Rahbari-Oskoui FF, Flessner MF, Bennett WM, Chapman AB; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Kidney Int. 2018 Mar;93(3):691-699. doi: 10.1016/j.kint.2017.09.027. Epub 2017 Dec 28.

5.

ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing.

Braun WE, Abebe KZ, Brosnahan G, Patterson CG, Chapman AB, Harris PC, Hogan MC, Perrone RD, Torres VE, Miskulin DC, Steinman TI, Winklhofer FT, Rahbari-Oskoui FF, Czarnecki PG, Bae KT, Grantham JJ, Flessner MF, Schrier RW.

Am J Kidney Dis. 2018 Feb;71(2):294-296. doi: 10.1053/j.ajkd.2017.09.008. Epub 2017 Dec 2. No abstract available.

6.

Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.

Chonchol M, Gitomer B, Isakova T, Cai X, Salusky I, Pereira R, Abebe K, Torres V, Steinman TI, Grantham JJ, Chapman AB, Schrier RW, Wolf M.

Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1461-1469. doi: 10.2215/CJN.12821216. Epub 2017 Jul 13.

7.

Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.

Li LX, Fan LX, Zhou JX, Grantham JJ, Calvet JP, Sage J, Li X.

J Clin Invest. 2017 Jun 30;127(7):2751-2764. doi: 10.1172/JCI90921. Epub 2017 Jun 12.

8.

Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.

Kline TL, Korfiatis P, Edwards ME, Bae KT, Yu A, Chapman AB, Mrug M, Grantham JJ, Landsittel D, Bennett WM, King BF, Harris PC, Torres VE, Erickson BJ; CRISP Investigators.

Kidney Int. 2017 Nov;92(5):1206-1216. doi: 10.1016/j.kint.2017.03.026. Epub 2017 May 20.

9.

Residual renal function: a paradigm shift.

Lowenstein J, Grantham JJ.

Kidney Int. 2017 Mar;91(3):561-565. doi: 10.1016/j.kint.2016.09.052. Review.

PMID:
28202171
10.

Performance of the CKD-EPI Equation to Estimate GFR in a Longitudinal Study of Autosomal Dominant Polycystic Kidney Disease.

Shen C, Landsittel D, Irazabal MV, Yu AS, Chapman AB, Mrug M, Grantham JJ, Bae KT, Bennett WM, Flessner MF, Torres VE; CRISP Investigators.

Am J Kidney Dis. 2017 Mar;69(3):482-484. doi: 10.1053/j.ajkd.2016.10.021. Epub 2016 Dec 24. No abstract available.

11.

Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.

Torres VE, Abebe KZ, Schrier RW, Perrone RD, Chapman AB, Yu AS, Braun WE, Steinman TI, Brosnahan G, Hogan MC, Rahbari FF, Grantham JJ, Bae KT, Moore CG, Flessner MF.

Kidney Int. 2017 Feb;91(2):493-500. doi: 10.1016/j.kint.2016.10.018. Epub 2016 Dec 16.

12.

Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.

Gansevoort RT, Meijer E, Chapman AB, Czerwiec FS, Devuyst O, Grantham JJ, Higashihara E, Krasa HB, Ouyang J, Perrone RD, Torres VE; TEMPO 3:4 Investigators.

Nephrol Dial Transplant. 2016 Nov;31(11):1887-1894. Epub 2015 Dec 17.

13.

The importance of total kidney volume in evaluating progression of polycystic kidney disease.

Grantham JJ, Torres VE.

Nat Rev Nephrol. 2016 Nov;12(11):667-677. doi: 10.1038/nrneph.2016.135. Epub 2016 Oct 3. Review.

14.

Experiences and Perspectives of Polycystic Kidney Disease Patients following a Diet of Reduced Osmoles, Protein, and Acid Precursors Supplemented with Water: A Qualitative Study.

Taylor JM, Ptomey L, Hamilton-Reeves JM, Sullivan DK, Creed C, Carlson SE, Wesson DE, Grantham JJ, Gibson CA.

PLoS One. 2016 Aug 18;11(8):e0161043. doi: 10.1371/journal.pone.0161043. eCollection 2016.

15.

Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease.

Grantham JJ, Chapman AB, Blais J, Czerwiec FS, Devuyst O, Gansevoort RT, Higashihara E, Krasa H, Zhou W, Ouyang J, Perrone RD, Torres VE; TEMPO 3:4 Investigators.

Nephrol Dial Transplant. 2017 Jun 1;32(6):969-975. doi: 10.1093/ndt/gfw060.

16.

The rebirth of interest in renal tubular function.

Lowenstein J, Grantham JJ.

Am J Physiol Renal Physiol. 2016 Jun 1;310(11):F1351-5. doi: 10.1152/ajprenal.00055.2016. Epub 2016 Mar 2. Review.

17.

Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.

Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS; TEMPO 3:4 Trial Investigators.

Clin J Am Soc Nephrol. 2016 May 6;11(5):803-11. doi: 10.2215/CJN.06300615. Epub 2016 Feb 23.

18.

Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease.

Heyer CM, Sundsbak JL, Abebe KZ, Chapman AB, Torres VE, Grantham JJ, Bae KT, Schrier RW, Perrone RD, Braun WE, Steinman TI, Mrug M, Yu AS, Brosnahan G, Hopp K, Irazabal MV, Bennett WM, Flessner MF, Moore CG, Landsittel D, Harris PC; HALT PKD and CRISP Investigators.

J Am Soc Nephrol. 2016 Sep;27(9):2872-84. doi: 10.1681/ASN.2015050583. Epub 2016 Jan 28.

19.

Diet and polycystic kidney disease: A pilot intervention study.

Taylor JM, Hamilton-Reeves JM, Sullivan DK, Gibson CA, Creed C, Carlson SE, Wesson DE, Grantham JJ.

Clin Nutr. 2017 Apr;36(2):458-466. doi: 10.1016/j.clnu.2016.01.003. Epub 2016 Jan 11.

20.

JASN's Silver Jubilee.

Nath KA, Neilson EG, Couser WG, Tisher CC, Grantham JJ.

J Am Soc Nephrol. 2015 Jul;26(7):1477-8. doi: 10.1681/ASN.2015050537. Epub 2015 Jun 4. No abstract available.

21.

Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease.

Chen L, Zhou X, Fan LX, Yao Y, Swenson-Fields KI, Gadjeva M, Wallace DP, Peters DJ, Yu A, Grantham JJ, Li X.

J Clin Invest. 2015 Jun;125(6):2399-412. doi: 10.1172/JCI80467. Epub 2015 May 11.

22.

The Future of Polycystic Kidney Disease Research--As Seen By the 12 Kaplan Awardees.

Antignac C, Calvet JP, Germino GG, Grantham JJ, Guay-Woodford LM, Harris PC, Hildebrandt F, Peters DJ, Somlo S, Torres VE, Walz G, Zhou J, Yu AS.

J Am Soc Nephrol. 2015 Sep;26(9):2081-95. doi: 10.1681/ASN.2014121192. Epub 2015 May 7.

23.

A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease.

Bhutani H, Smith V, Rahbari-Oskoui F, Mittal A, Grantham JJ, Torres VE, Mrug M, Bae KT, Wu Z, Ge Y, Landslittel D, Gibbs P, O'Neill WC, Chapman AB; CRISP Investigators.

Kidney Int. 2015 Jul;88(1):146-51. doi: 10.1038/ki.2015.71. Epub 2015 Apr 1.

24.

Blood pressure in early autosomal dominant polycystic kidney disease.

Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB; HALT-PKD Trial Investigators.

N Engl J Med. 2014 Dec 11;371(24):2255-66. doi: 10.1056/NEJMoa1402685. Epub 2014 Nov 15.

25.

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, Perrone RD; HALT-PKD Trial Investigators.

N Engl J Med. 2014 Dec 11;371(24):2267-76. doi: 10.1056/NEJMoa1402686. Epub 2014 Nov 15.

26.

Rationale for early treatment of polycystic kidney disease.

Grantham JJ.

Pediatr Nephrol. 2015 Jul;30(7):1053-62. doi: 10.1007/s00467-014-2882-8. Epub 2014 Jul 15. Review.

PMID:
25022529
27.

Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.

Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, Bae KT, Chapman AB, Grantham JJ, Mrug M, Hogan MC, El-Zoghby ZM, Harris PC, Erickson BJ, King BF, Torres VE; CRISP Investigators.

J Am Soc Nephrol. 2015 Jan;26(1):160-72. doi: 10.1681/ASN.2013101138. Epub 2014 Jun 5.

28.

Tubular obstruction leads to progressive proximal tubular injury and atubular glomeruli in polycystic kidney disease.

Galarreta CI, Grantham JJ, Forbes MS, Maser RL, Wallace DP, Chevalier RL.

Am J Pathol. 2014 Jul;184(7):1957-66. doi: 10.1016/j.ajpath.2014.03.007. Epub 2014 May 9.

29.

Novel methodology to evaluate renal cysts in polycystic kidney disease.

Bae KT, Sun H, Lee JG, Bae K, Wang J, Tao C, Chapman AB, Torres VE, Grantham JJ, Mrug M, Bennett WM, Flessner MF, Landsittel DP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease.

Am J Nephrol. 2014;39(3):210-7. doi: 10.1159/000358604. Epub 2014 Feb 22.

30.

Novel approach to estimate kidney and cyst volumes using mid-slice magnetic resonance images in polycystic kidney disease.

Bae KT, Tao C, Wang J, Kaya D, Wu Z, Bae JT, Chapman AB, Torres VE, Grantham JJ, Mrug M, Bennett WM, Flessner MF, Landsittel DP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Am J Nephrol. 2013;38(4):333-41. doi: 10.1159/000355375. Epub 2013 Oct 5.

31.

Smac-mimetic-induced epithelial cell death reduces the growth of renal cysts.

Fan LX, Zhou X, Sweeney WE Jr, Wallace DP, Avner ED, Grantham JJ, Li X.

J Am Soc Nephrol. 2013 Dec;24(12):2010-22. doi: 10.1681/ASN.2013020176. Epub 2013 Aug 29.

32.

Segmentation of individual renal cysts from MR images in patients with autosomal dominant polycystic kidney disease.

Bae K, Park B, Sun H, Wang J, Tao C, Chapman AB, Torres VE, Grantham JJ, Mrug M, Bennett WM, Flessner MF, Landsittel DP, Bae KT; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Clin J Am Soc Nephrol. 2013 Jul;8(7):1089-97. doi: 10.2215/CJN.10561012. Epub 2013 Mar 21.

33.

The medicinal use of water in renal disease.

Wang CJ, Grantham JJ, Wetmore JB.

Kidney Int. 2013 Jul;84(1):45-53. doi: 10.1038/ki.2013.23. Epub 2013 Feb 20. Review.

34.

Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study.

Kistler AD, Serra AL, Siwy J, Poster D, Krauer F, Torres VE, Mrug M, Grantham JJ, Bae KT, Bost JE, Mullen W, Wüthrich RP, Mischak H, Chapman AB.

PLoS One. 2013;8(1):e53016. doi: 10.1371/journal.pone.0053016. Epub 2013 Jan 10. Erratum in: PLoS One. 2013;8(8). doi:10.1371/annotation/9281c713-d253-4a1a-8255-92e691e77a24.

35.

Tolvaptan in patients with autosomal dominant polycystic kidney disease.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators.

N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3.

36.

Detected renal cysts are tips of the iceberg in adults with ADPKD.

Grantham JJ, Mulamalla S, Grantham CJ, Wallace DP, Cook LT, Wetzel LH, Fields TA, Bae KT.

Clin J Am Soc Nephrol. 2012 Jul;7(7):1087-93. doi: 10.2215/CJN.00900112. Epub 2012 May 10.

37.

Bully renal cysts knock down urine-concentrating capacity in the early rounds.

Grantham JJ.

Clin J Am Soc Nephrol. 2012 Jun;7(6):875-7. doi: 10.2215/CJN.03720412. Epub 2012 May 10. No abstract available.

38.

Solitary renal cysts: worth a second look?

Grantham JJ.

Am J Kidney Dis. 2012 May;59(5):593-4. doi: 10.1053/j.ajkd.2012.02.002. No abstract available.

PMID:
22507646
39.

Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.

Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, Li J, King BF, Martin D, Wetzel LH, Lockhart ME, Harris PC, Moxey-Mims M, Flessner M, Bennett WM, Grantham JJ.

Clin J Am Soc Nephrol. 2012 Mar;7(3):479-86. doi: 10.2215/CJN.09500911. Epub 2012 Feb 16.

40.

Evaluation of urine biomarkers of kidney injury in polycystic kidney disease.

Parikh CR, Dahl NK, Chapman AB, Bost JE, Edelstein CL, Comer DM, Zeltner R, Tian X, Grantham JJ, Somlo S.

Kidney Int. 2012 Apr;81(8):784-90. doi: 10.1038/ki.2011.465. Epub 2012 Jan 18.

41.

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.

Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS; TEMPOFormula and 156-05-002 Study Investigators.

Clin J Am Soc Nephrol. 2011 Oct;6(10):2499-507. doi: 10.2215/CJN.03530411. Epub 2011 Sep 8.

42.

Why kidneys fail in autosomal dominant polycystic kidney disease.

Grantham JJ, Mulamalla S, Swenson-Fields KI.

Nat Rev Nephrol. 2011 Aug 23;7(10):556-66. doi: 10.1038/nrneph.2011.109. Review.

PMID:
21862990
43.

Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.

Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS.

Am J Kidney Dis. 2011 May;57(5):692-9. doi: 10.1053/j.ajkd.2010.11.029. Epub 2011 Feb 17.

PMID:
21333426
44.

mTOR inhibitors and autosomal dominant polycystic kidney disease.

Grantham JJ, Bennett WM, Perrone RD.

N Engl J Med. 2011 Jan 20;364(3):286-7; author reply 287-9. doi: 10.1056/NEJMc1010845. No abstract available.

PMID:
21247328
45.

Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.

Torres VE, Grantham JJ, Chapman AB, Mrug M, Bae KT, King BF Jr, Wetzel LH, Martin D, Lockhart ME, Bennett WM, Moxey-Mims M, Abebe KZ, Lin Y, Bost JE; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Clin J Am Soc Nephrol. 2011 Mar;6(3):640-7. doi: 10.2215/CJN.03250410. Epub 2010 Nov 18.

46.

Water prescription in autosomal dominant polycystic kidney disease: a pilot study.

Wang CJ, Creed C, Winklhofer FT, Grantham JJ.

Clin J Am Soc Nephrol. 2011 Jan;6(1):192-7. doi: 10.2215/CJN.03950510. Epub 2010 Sep 28.

47.

Evidence of extraordinary growth in the progressive enlargement of renal cysts.

Grantham JJ, Cook LT, Wetzel LH, Cadnapaphornchai MA, Bae KT.

Clin J Am Soc Nephrol. 2010 May;5(5):889-96. doi: 10.2215/CJN.00550110. Epub 2010 Apr 1.

48.

Imaging for the prognosis of autosomal dominant polycystic kidney disease.

Bae KT, Grantham JJ.

Nat Rev Nephrol. 2010 Feb;6(2):96-106. doi: 10.1038/nrneph.2009.214. Review.

PMID:
20111050
49.

The Birth and Early Development of JASN.

Grantham JJ, Sullivan LP.

J Am Soc Nephrol. 2010 Jan;21(1):1-2. doi: 10.1681/ASN.2009090910. Epub 2009 Dec 10. No abstract available.

50.

A case for water in the treatment of polycystic kidney disease.

Torres VE, Bankir L, Grantham JJ.

Clin J Am Soc Nephrol. 2009 Jun;4(6):1140-50. doi: 10.2215/CJN.00790209. Epub 2009 May 14. Review.

Supplemental Content

Loading ...
Support Center